Drugmaker Eli Lilly and Co. said Monday that its first-quarter earnings fell 15 percent due mainly to some one-time charges, but revenue climbed 6 percent to $5.84 billion on the back of sales increases from several key drugs.
Sales of cancer treatment Gemzar plunged 46 percent after the drug lost U.S. patent protection last fall. But anti-psychotic Zyprexa was once again the top seller, with sales growing 6 percent to $1.28 billion. Here's a breakdown of where the rest of the sales growth came from for the Indianapolis company.
_ Antidepressant Cymbalta, up 13 percent, to $908.8 million.
_ Insulin Humulin, up 12 percent, to $289.8 million.
_ Osteoporosis treatment Forteo, up 11 percent, to $216.1 million.
_ Another osteoporosis drug, Evista, up 10 percent, to $266.1 million.
_ Erectile dysfunction treatment Cialis, up 6 percent, to $434.4 million.